TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer

Published:2019-09-19 Issue:9 Volume:14 Page:e0213488
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lee Geun Taek,Rosenfeld Jeffrey A.,Kim Won Tae,Kwon Young Suk,Palapattu Ganesh,Mehra Rohit,Kim Wun-Jae,Kim Isaac Yi

Funder

U.S. Department of Defense

Foundation for the National Institutes of Health

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference54 articles.

1. Cancer Statistics, 2017;RL Siegel;CA Cancer J Clin,2017

2. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma;ED Crawford;N Engl J Med,1989

3. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group;P Schellhammer;Urology,1996

4. Mechanisms of androgen-refractory prostate cancer;JD Debes;N Engl J Med,2004

5. The development of androgen-independent prostate cancer;BJ Feldman;Nat Rev Cancer,2001

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

2. Investigating Carcinoid Tumor Oncogenesis through the lens of Developmental Dynamics involved in Small Intestinal Neuroendocrine Cells;2024-03-29

3. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC;Nature Communications;2024-01-08

4. In vitro study of miRNA-369-3p targeting TCF4 regulating the malignant biological behavior of colon cancer cells;Journal of Gastrointestinal Oncology;2023-10

5. Wnt Signaling and Therapeutic Resistance in Castration-Resistant Prostate Cancer;Current Pharmacology Reports;2023-09-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3